Arch Therapeutics

OverviewSuggest Edit

Arch Therapeutics is a biotechnology company developing an innovative, elegant, and superior approach to the rapid cessation of bleeding (hemostasis) and control of fluid leakage (sealant) during surgery and trauma care.
Arch intends to transform the landscape of interventional healthcare with products to seal and protect leaking and bleeding tissue. Arch’s solution elegantly controls the movement of these fluids and substances.
The first product, AC5 Surgical Hemostatic Device, is designed to achieve hemostasis in minimally invasive (laparoscopic) and open surgical procedures and is intended to be regulated as a medical device. Surgeons would deem the product a “must have” because of its tremendous features, making it very different and far advanced compared to anything currently on the market. AC5 stops bleeding promptly. Unlike many competitive products, it conforms to irregular wound geometry, allows for normal healing, and helps maintain a clear field of vision directly into the wound area.

TypePrivate
Founded2006
HQFramingham, US
Websitearchtherapeutics.com

Latest Updates

Employees (est.) (Mar 2017)5
Revenue (FY, 2016)$0

Key People/Management at Arch Therapeutics

Terrence W. Norchi

Terrence W. Norchi

President, CEO, Director, Co-Founder
Avtar Dhillon

Avtar Dhillon

Chairman
Show more

Arch Therapeutics Office Locations

Arch Therapeutics has an office in Framingham
Framingham, US (HQ)
235 Walnut St
Show all (1)

Arch Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2006

Arch Therapeutics total Funding

$5.9 m

Arch Therapeutics latest funding size

$3 m

Time since last funding

4 years ago
Arch Therapeutics's latest funding round in July 2015 was reported to be $3 m. In total, Arch Therapeutics has raised $5.9 m
View all funding rounds

Arch Therapeutics Revenue

USD

Net income (Q2, 2019)

170.0k

EBIT (Q2, 2019)

(1.5m)

Cash (31-Mar-2019)

2.0m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

General and administrative expense

1.5m3.1m3.7m4.4m5.2m4.6m

R&D expense

218.9k1.5m1.8m1.7m2.1m2.9m

Operating expense total

1.7m4.6m5.5m6.1m7.3m7.4m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Revenue

General and administrative expense

523.4k808.5k826.0k870.4k853.2k813.1k865.5k868.4k1.3m1.0m1.5m1.3m1.0m999.4k986.1k1.2m878.6k

R&D expense

257.2k487.1k320.3k399.7k402.5k525.1k414.0k386.3k438.6k349.3k709.9k534.6k580.9k1.0m634.0k589.2k628.8k

Operating expense total

780.7k1.3m1.1m1.3m1.3m1.3m1.3m1.3m1.7m1.4m2.2m1.8m1.6m2.0m1.6m1.8m1.5m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

557.3k833.5k4.0m5.0m6.0m4.7m

Accounts Receivable

50.0m

Inventories

19.6k43.5k42.9k107.8k85.3k

Current Assets

1.6m877.0k4.0m5.1m6.1m4.8m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Cash

945.4k2.6m1.8m782.7k573.6k3.3m2.8m1.7m5.7m3.8m7.2m6.2m5.0m3.4m6.5m3.4m2.0m

Current Assets

985.0k2.7m1.8m824.4k606.0k3.3m2.9m1.8m5.9m3.9m7.6m6.3m5.0m3.4m6.6m3.6m2.4m

PP&E

322.0322.04.2k3.8k3.5k9.9k15.2k19.1k15.5k13.7k

Total Assets

995.4k2.7m1.8m824.4k606.0k3.3m2.9m1.8m5.9m3.9m7.6m6.3m5.0m3.5m6.6m3.6m2.4m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(1.9m)(8.1m)(2.9m)(6.0m)(7.8m)(4.8m)

Depreciation and Amortization

586.0322.01.5k5.3k

Inventories

(16.3k)(13.8k)551.0(64.9k)85.3k

Accounts Payable

56.3k(138.9k)55.9k137.4k(110.0k)(103.9k)
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Net Income

(808.4k)(9.2m)(8.8m)379.1k(454.8k)(1.9m)(1.2m)(2.4m)(4.2m)(1.4m)(3.3m)(5.0m)389.2k(1.2m)(3.4m)(2.6m)(2.4m)

Depreciation and Amortization

322.0119.0477.0835.0724.01.9k3.6k1.8k3.6k

Accounts Payable

(5.2k)(210.6k)(148.8k)118.4k28.3k323.9k36.1k(96.1k)21.3k(102.6k)(247.8k)(168.8k)24.4k52.6k(81.7k)(30.3k)14.7k

Cash From Operating Activities

(611.9k)(1.6m)(2.4m)(850.8k)(1.8m)(2.6m)(1.1m)(2.3m)(3.7m)(1.4m)(3.4m)(4.4m)(1.1m)(2.7m)(4.1m)(1.3m)(2.7m)
USDY, 2019

Financial Leverage

-12.1 x
Show all financial metrics

Arch Therapeutics Online and Social Media Presence

Embed Graph

Arch Therapeutics News and Updates

Arch Therapeutics, Inc. $2.8 Million Registered Direct Offering

FRAMINGHAM, Mass., May 13, 2019 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH)(“Arch” or the “Company”), a developer of novel liquid, gel and solid hemostatic and wound care devices, today announced the pricing of registered direct offering of approximately 8.6 million units, each unit …

Arch Therapeutics Announces Attendance at 2019 Symposium on Advanced Wound Care Conference (SAWC) and Release of a New AC5TM Topical Gel Video

FRAMINGHAM, Mass., April 24, 2019 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of products for dermal science and biosurgical applications, today announced that the company will attend The Symposium on Advanced Wound Care Spring (SAWC) from May 7-1…

Arch Therapeutics to Provide Corporate Update at the 31st Annual ROTH Conference

FRAMINGHAM, Mass., March 11, 2019 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will be featured as a presenting company at the 31st Annual ROTH Conference. The conference is being he…

Arch Therapeutics to Provide Corporate Update at the 2019 BIO CEO & Investor Conference

FRAMINGHAM, Mass., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will be featured as a presenting company at the 2019 BIO CEO & Investor Conference. The conference i…

Arch Therapeutics to Provide Corporate Update at the 11th Annual Biotech Showcase™ 2019 Conference on January 8th, 2019

FRAMINGHAM, Mass., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will be featured as a presenting company at the 11th Annual Biotech ShowcaseTM 2019 Conference. The conf…

Arch Therapeutics Receives 510(k) Clearance from the US FDA for AC5™ Topical Gel

AC5™ provides a new option for the treatment of topical wounds AC5™ provides a new option for the treatment of topical wounds
Show more

Arch Therapeutics Blogs

Arch Therapeutics Announces 510(k) Submission to the U.S. FDA for AC5™ Topical Gel

FRAMINGHAM, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel liquid, gel and solid hemostatic and wound care devices, today announced that the Company submitted a 510(k) notification to the U.S. Food and Drug Administrati…

Arch Therapeutics to Provide Corporate Update at the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, October 2, 2018

FRAMINGHAM, Mass., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will be featured as a presenting company at the Ladenburg Thalmann 2018 Healthcare Conference. The con…

Arch Therapeutics Reports Topline Results from Skin Sensitization Study of AC5

Study finds no evidence of irritation or allergic reaction in any enrolled subject FRAMINGHAM, Mass., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of liquid, gel and solid hemostatic and wound care devices, today announced topline …

Arch Therapeutics to Provide Corporate Update at the H.C. Wainwright 20th Annual Global Investment Conference on Wednesday, September 5, 2018

FRAMINGHAM, Mass., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will be featured as a presenting company at the H.C. Wainwright 20th Annual Global Investment Conferenc…

Arch Therapeutics Announces Poster Presentation at the 2018 Military Health System Research Symposium on Tuesday, August 21, 2018

Early stage ophthalmology and anti-inflammation pipeline projects highlighted FRAMINGHAM, Mass., Aug. 16, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) (“Arch” or the “Company”), developer of AC5™ Topical Gel  (“AC5™”), today announced that new research involving AC5™ will be pre…

Arch Therapeutics Appoints Healthcare Industry Executive Punit Dhillon to Board of Directors

Medical device and biopharma drug development, M&A experience enhance Arch FRAMINGHAM, Mass., July 20, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) (“Arch” or the “Company”), developer of the AC5 Surgical Hemostatic Device™ (“AC5™”), today announced the appointment of Punit …
Show more

Arch Therapeutics Frequently Asked Questions

  • When was Arch Therapeutics founded?

    Arch Therapeutics was founded in 2006.

  • Who are Arch Therapeutics key executives?

    Arch Therapeutics's key executives are Terrence W. Norchi and Avtar Dhillon.

  • How many employees does Arch Therapeutics have?

    Arch Therapeutics has 5 employees.

  • Who are Arch Therapeutics competitors?

    Competitors of Arch Therapeutics include Intersect ENT, ViewRay and American Renal Associates.

  • Where is Arch Therapeutics headquarters?

    Arch Therapeutics headquarters is located at 235 Walnut St, Framingham.

  • Where are Arch Therapeutics offices?

    Arch Therapeutics has an office in Framingham.

  • How many offices does Arch Therapeutics have?

    Arch Therapeutics has 1 office.